Evaluating BRAF Mutations as Predictors of Efficacy in Cetuximab-Treated Colorectal Cancer Patients: A Retrospective Study of Tissues From CALGB / SWOG
- To determine, among patients with advanced CRC, whether the effect of treatment
(cetuximab vs bevacizumab) on progression-free survival (PFS) depends on tumor BRAF
V600E mutational status.
- To study the relationships between tumor BRAF V600E mutational status, OS, and tumor
OUTLINE: This is a multicenter study.
Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are
analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and
outcome data from patients enrolled on CALGB-C80405.
Progression-free survival as measured by RECIST
Najjia N. Mahmoud, MD
Abramson Cancer Center of the University of Pennsylvania